We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600298:SSEAngel Yeast Co., Ltd. Class A Analysis

Data as of 2026-03-12 - not real-time

CN¥42.25

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Angel Yeast trades at CNY 42.25, comfortably above its 30‑day DCF fair value of CNY 30.58 and its 20‑day SMA of CNY 43.08, indicating the market is pricing in optimism despite modest fundamentals. The stock sits near the computed support of CNY 41.21 and well below the resistance of CNY 44.75, while the MACD shows a bearish crossover (line -0.38 vs. signal -0.28) and the RSI hovers at 46, suggesting limited upside momentum in the short run. Fundamentally, revenue is growing only 4% YoY, margins are modest (gross 24.8%, operating 10.5%) and free cash flow is negative, though operating cash flow remains positive; the company carries a high debt‑to‑equity ratio of 64.9% and a payout ratio of ~32%.
The valuation metrics reinforce an overvalued picture: PE 24.6 and PB 3.17 exceed typical peer averages for a consumer‑defensive, low‑growth business, while the dividend yield of 1.3% offers limited cushion. Volatility is elevated at 31% over the past 30 days, but beta is near zero (‑0.09), indicating low market‑wide systematic risk. Overall, the stock appears priced for limited upside, with risk stemming from its debt load, thin free cash flow, and a technical backdrop that is neutral to slightly bearish.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram and proximity to support level
  • Price above DCF fair value suggesting limited upside
  • Elevated 30‑day volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Modest 4% revenue growth and stable but thin margins
  • High debt‑to‑equity ratio increasing financial risk
  • Dividend yield low relative to valuation premium

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Diversified product portfolio in a defensive sector
  • Negative free cash flow and elevated leverage
  • Valuation remains above intrinsic estimates

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin9.26%
P/E Ratio24.6
ROE13.13%
ROA4.50%
Debt/Equity64.88
P/B Ratio3.2
Op. Cash FlowCN¥2.7B
Free Cash FlowCN¥-223824768

Technical Analysis

TrendNeutral
RSI46.0
SupportCN¥41.21
ResistanceCN¥44.75
MA 20CN¥43.08
MA 50CN¥43.57
MA 200CN¥39.61
MACDBearish
VolumeIncreasing
Fear & Greed Index75.48

Valuation

Fair ValueCN¥30.58
GradeOvervalued
TypeValue
Dividend Yield1.30%

Risk Assessment

Beta-0.09
Volatility31.12%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.